Contact
searchSearch
HMP Global

Advertisement

ADVERTISEMENT

News

News
IceCure Announces Regulatory Filing Submission for Approval of Prosense® in Canada for Indications Including Ablation of Benign and Malignant Breast Tumors
07/25/2022
Canadian hospitals and health care providers have expressed strong interest in ProSense® as they seek minimally invasive treatments for breast and other tumors CAESAREA, Israel, July 25, 2022 /PRNewswire/ -- IceCure Medical...
Canadian hospitals and health care providers have expressed strong interest in ProSense® as they seek minimally invasive treatments for breast and other tumors CAESAREA, Israel, July 25, 2022 /PRNewswire/ -- IceCure Medical...
Canadian hospitals and health...
07/25/2022
IO Learning
News
JACC: Adult Cancer Survivors Have Higher Risk of Cardiovascular Disease Than Those Without Cancer, Study Shows
06/30/2022
Adult survivors of cancer have a higher risk of heart failure and other cardiovascular diseases (CVD) later in life than adults without cancer, according to results of a large study led by Johns Hopkins Medicine researchers.
Adult survivors of cancer have a higher risk of heart failure and other cardiovascular diseases (CVD) later in life than adults without cancer, according to results of a large study led by Johns Hopkins Medicine researchers.
Adult survivors of cancer have a...
06/30/2022
Cath Lab Digest
News
Countries Pledge € 9 Million for IAEA Cancer Care Initiative
06/14/2022
Vienna, Austria Six countries have pledged more than €9 million in support of a new International Atomic Energy Agency (IAEA) initiative – Rays of Hope – launched earlier this year to address a wide global gap in access to cancer care....
Vienna, Austria Six countries have pledged more than €9 million in support of a new International Atomic Energy Agency (IAEA) initiative – Rays of Hope – launched earlier this year to address a wide global gap in access to cancer care....
Vienna, Austria Six countries...
06/14/2022
IO Learning

Advertisement

News
PANCREATIC CANCER ACTION NETWORK RALLIES ADVOCATES FROM ALL 50 STATES TO URGE CONGRESS TO INCREASE FUNDING FOR PANCREATIC CANCER RESEARCH
06/13/2022
Increased Federal Funding Leads to Higher Pancreatic Cancer Survival Rates
Increased Federal Funding Leads to Higher Pancreatic Cancer Survival Rates
Increased Federal Funding Leads...
06/13/2022
IO Learning
News
HistoSonics Hits Pivotal Clinical Trial Milestone In #HOPE4LIVER Studies
06/03/2022
Company Continues to Build as It Prepares for FDA Submission and Clearance of Its Breakthrough Therapy
Company Continues to Build as It Prepares for FDA Submission and Clearance of Its Breakthrough Therapy
Company Continues to Build as It...
06/03/2022
IO Learning
News
HistoSonics Announces Agreement with GE Healthcare
05/23/2022
HistoSonics Breakthrough Liver Therapy System to Utilize GE's LOGIQ™ E10 for Real-Time Imaging Guidance and Treatment Verification
HistoSonics Breakthrough Liver Therapy System to Utilize GE's LOGIQ™ E10 for Real-Time Imaging Guidance and Treatment Verification
HistoSonics Breakthrough Liver...
05/23/2022
IO Learning

Advertisement

News
IceCure Medical Presents ICE3 Breast Cancer Trial Interim Data, Hosts Cryoablation Symposium & Conducts Hands-On ProSense® Training Sessions at the European Conference on Interventional Oncology
04/27/2022
NEWS PROVIDED BY IceCure Medical  Apr 27, 2022, 09:00 ET CAESAREA, Israel, April 27, 2022 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of...
NEWS PROVIDED BY IceCure Medical  Apr 27, 2022, 09:00 ET CAESAREA, Israel, April 27, 2022 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of...
NEWS PROVIDED BY IceCure...
04/27/2022
IO Learning
News
ABK Biomedical Announces First Patient Treated in First-in-Human Clinical Study with Eye90 microspheres™ for treatment of liver tumors
04/19/2022
NEWS PROVIDED BY ABK Biomedical Inc.  Apr 19, 2022, 09:12 ET HALIFAX, NS, April 19, 2022 /PRNewswire/ -  ABK Biomedical, Inc., an innovative, clinical-stage medical device company dedicated to the...
NEWS PROVIDED BY ABK Biomedical Inc.  Apr 19, 2022, 09:12 ET HALIFAX, NS, April 19, 2022 /PRNewswire/ -  ABK Biomedical, Inc., an innovative, clinical-stage medical device company dedicated to the...
NEWS PROVIDED BY ABK...
04/19/2022
IO Learning
News
EDDA Technology is proud to announce IQQA®-BodyImaging Provides 3D assessment in ACCLAIM Trial conducted by SIO
04/18/2022
NEWS PROVIDED BY EDDA Technology, Inc.  Apr 18, 2022, 18:16 ET PRINCETON, N.J., April 18, 2022 /PRNewswire/ -- EDDA Technology, a global leading provider in advanced imaging-guided precision treatment solutions,...
NEWS PROVIDED BY EDDA Technology, Inc.  Apr 18, 2022, 18:16 ET PRINCETON, N.J., April 18, 2022 /PRNewswire/ -- EDDA Technology, a global leading provider in advanced imaging-guided precision treatment solutions,...
NEWS PROVIDED BY EDDA...
04/18/2022
IO Learning

Advertisement

News
FDA Clears Four New Coronary Micro Support Catheters
04/12/2022
Non-tapered metal-alloy support catheter platform receives FDA clearance for use in coronary and peripheral vasculature. Transit Scientific now has one of the largest platforms of FDA cleared microcatheters in the industry.
Non-tapered metal-alloy support catheter platform receives FDA clearance for use in coronary and peripheral vasculature. Transit Scientific now has one of the largest platforms of FDA cleared microcatheters in the industry.
Non-tapered metal-alloy support...
04/12/2022
Cath Lab Digest

Subscribe

IO Learning Newsletter

News

News
Novel Endovascular Robotic Surgical System Reaches Midpoint of Pivotal Clinical Trial
09/20/2024
The ACCESS-PVI trial of LIBERTY® Endovascular Robotic Surgical System has enrolled and completed follow-up for 50% of patients.
The ACCESS-PVI trial of LIBERTY® Endovascular Robotic Surgical System has enrolled and completed follow-up for 50% of patients.
The ACCESS-PVI trial of LIBERTY®...
09/20/2024
IO Learning
News
Histotripsy Demonstrates Technical Success, Safety for Primary and Metastatic Liver Tumors
09/04/2024
According to results from the parallel #HOPE4LIVER trials, the novel ablation technique of histotripsy met coprimary end points for technical success and safety among patients with primary and metastatic liver tumors.
According to results from the parallel #HOPE4LIVER trials, the novel ablation technique of histotripsy met coprimary end points for technical success and safety among patients with primary and metastatic liver tumors.
According to results from the...
09/04/2024
IO Learning
News
Sorafenib Plus Transarterial Chemoembolization Improves Survival Outcomes, Response Among Patients With Recurrent Hepatocellular Carcinoma
07/29/2024
According to a phase 3 trial, the addition of sorafenib to TACE improved survival outcomes and response among patients with recurrent intermediate-stage hepatocellular carcinoma after R0 initial hepatectomy and microvascular invasion.
According to a phase 3 trial, the addition of sorafenib to TACE improved survival outcomes and response among patients with recurrent intermediate-stage hepatocellular carcinoma after R0 initial hepatectomy and microvascular invasion.
According to a phase 3 trial,...
07/29/2024
Oncology
News
Thermal Ablation Over Surgical Resection for Patients With Smaller Colorectal Liver Metastases
07/18/2024
According to the phase 3 COLLISION trial, thermal ablation for smaller colorectal liver metastases reduced morbidity and mortality without compromising survival outcomes compared to surgical resection.
According to the phase 3 COLLISION trial, thermal ablation for smaller colorectal liver metastases reduced morbidity and mortality without compromising survival outcomes compared to surgical resection.
According to the phase 3...
07/18/2024
IO Learning
News
Manageable Safety Across Treatment Periods for Durvalumab, Bevacizumab, and TACE Regimen Among Patients With Unresectable Hepatocellular Carcinoma
07/17/2024
According to a post-hoc, exploratory analysis of safety by treatment period in the EMERALD-1 study, durvalumab plus bevacizumab plus transarterial chemoembolization had a manageable safety profile across both treatment periods among patients...
According to a post-hoc, exploratory analysis of safety by treatment period in the EMERALD-1 study, durvalumab plus bevacizumab plus transarterial chemoembolization had a manageable safety profile across both treatment periods among patients...
According to a post-hoc,...
07/17/2024
IO Learning
News
Transit Scientific Announces First Worldwide Case Performed with Innovative Embolic-Delivery Microcatheter
07/09/2024
Transit Scientific Press Release Park City, Utah USA, July 9, 2024 – Transit Scientific, a Utah-based medical device company specializing in innovative solutions for vascular procedures, proudly announces the successful debut of XO...
Transit Scientific Press Release Park City, Utah USA, July 9, 2024 – Transit Scientific, a Utah-based medical device company specializing in innovative solutions for vascular procedures, proudly announces the successful debut of XO...
Transit Scientific Press...
07/09/2024
Vascular Disease Management
Imaging Systems
University Hospitals Cleveland, Siemens Healthineers in New Alliance to Improve Oncology, Cardiovascular and Neurovascular Care for Patients
05/08/2024

Siemens Healthineers and University Hospitals Cleveland News

Siemens Healthineers and University H...
The new alliance will enhance cardiovascular services of the UH Harrington Heart & Vascular Institute with the world’s first clinically available photon-counting CT scanner and the new dual-source CT scanner.
The new alliance will enhance cardiovascular services of the UH Harrington Heart & Vascular Institute with the world’s first clinically available photon-counting CT scanner and the new dual-source CT scanner.
The new alliance will enhance...
05/08/2024
Cath Lab Digest
News
Histotripsy Treatment for Primary and Metastatic Liver Tumors
04/25/2024
At the 2023 CIRSE Annual Meeting, first results from the #HOPE4LIVER trial evaluating histotripsy for primary and metastatic liver tumors were reported.
At the 2023 CIRSE Annual Meeting, first results from the #HOPE4LIVER trial evaluating histotripsy for primary and metastatic liver tumors were reported.
At the 2023 CIRSE Annual...
04/25/2024
IO Learning
News
First-of-Its-Kind Surgical Foam Technology Improves Operating Room Workflow
04/24/2024

Syntervention Press Release

Syntervention Press Release
Rocky Mount, North Carolina, USA, April 24, 2024 — Syntervention, Inc., a medical device company focused on meeting critical needs in the healthcare space, announces the impact of using its SWICKER® Radiopaque Surgical Foam Sponge in open...
Rocky Mount, North Carolina, USA, April 24, 2024 — Syntervention, Inc., a medical device company focused on meeting critical needs in the healthcare space, announces the impact of using its SWICKER® Radiopaque Surgical Foam Sponge in open...
Rocky Mount, North Carolina,...
04/24/2024
EP Lab Digest
News
Fluidx Medical Reveals New Embolic Platform for Internal Bleeding, Tumor Treatment, and Other Uses
11/30/2023
Salt Lake City (UT) – Fluidx Medical today released information about their new ULTRA™ embolic platform designed to make therapeutic embolization procedures safer, better, and faster.   Embolization is a minimally invasive...
Salt Lake City (UT) – Fluidx Medical today released information about their new ULTRA™ embolic platform designed to make therapeutic embolization procedures safer, better, and faster.   Embolization is a minimally invasive...
Salt Lake City (UT) – Fluidx...
11/30/2023
Vascular Disease Management

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use